Technology helps hip, knee replacements last longer

February 25, 2019

Published by Harvest ETFs

Hip and knee replacements are among the most common forms of surgery. Steady advances in medical science mean the procedures are becoming less intrusive and patients heal faster as lighter, stronger implants have become available. 

One question doctors have found hard to answer is how long the implants last. That information helps patients decide when they should have the surgery. This is becoming a more important consideration as the population ages and life expectancy rises.

A University of Bristol study answers the question. Researchers writing in The Lancet medical journal, looked at six countries which held at least 15 years of data – Australia, Finland, Denmark, New Zealand, Norway and Sweden.

They found that 80% of knee replacements lasted 25 years and 90% lasted 20 years. When it came to hips, nearly 60% lasted for 25 years and 70% lasted 20 years. This is much longer than believed.

For investors, increasing longevity and hip and knee surgery are a trend among broader healthcare opportunities.

The Canadian Health Information Institute (CHII), a non-profit group based in Ottawa, says Canadian hip and knee replacements are growing by double digits. They are being performed on 123,000 Canadians each year at a cost of $1 billion to the healthcare system. BBC Health recently reported that nearly 200,000 hip and knee operations are performed in  England and Wales each year.

In the UK, most are carried out on people between 60 and 80 years old, which is similar to CIHI’s latest report which notes that two-thirds of hip replacements are going to patients 65 or older. CIHI says knee replacements having a younger demographic where half of all patients are 50 or older.

 The Harvest Healthcare Leaders Income ETF (TSX: HHL, HHL.U) aims to capture growth in this sector. The Fund invests in the stocks of 20 global healthcare issuers that have a minimum market capitalization of US$5 billion.  

Two of the top holdings in the ETF are Stryker Corp., with a market cap of US$70.31 billion and Boston Scientific Corp. with a market cap of US $56.07 billion. Both offer a broad range of medical devices and equipment and are benefiting from the medical needs of an aging developed world population and growing emerging market one. – AM

For more on Harvest Portfolio products, click here.

The views and/or opinions expressed in the blog are of a general nature and are for informational purposes only. Blog contents should not be considered as advice and/or a recommendation to purchase or sell the mentioned securities or used to engage in personal investment strategies. Investors should consult their investment advisor before making any investment decision.  

You may also like…


For Information Purposes Only. Commissions, management fees and expenses all may be associated with investing in HARVEST Exchange Traded Funds (managed by Harvest Portfolios Group Inc.) Please read the relevant prospectus before investing. The funds are not guaranteed, their values change frequently and past performance may not be repeated. This communication should not be considered as advice and/or a recommendation to purchase or sell the mentioned securities or used to engage in personal investment strategies. Tax, investment and all other decisions should be made with guidance from a qualified professional.

Certain statements in the Harvest Blog are forward looking Forward-looking statements (“FLS”) are statements that are predictive in nature, depend upon or refer to future events or conditions, or that include words such as “may,” “will,” “should,” “could,” “expect,” “anticipate,” “intend,” “plan,” “believe,” or  “estimate,” or other similar expressions. Statements that look forward in time or include anything other than historical information are subject to risks and uncertainties, and actual results, actions or events could differ materially from those set forth in the FLS.

FLS are not guarantees of future performance and are by their nature based on numerous assumptions, which include, amongst other things, that (i) the Fund can attract and maintain investors and have sufficient capital under management to effect their investment strategies, (ii) the investment strategies will produce the results intended by the portfolio managers, and (iii) the markets will react and perform in a manner consistent with the investment strategies. Although the FLS contained herein are based upon what the portfolio manager believe to be reasonable assumptions, the portfolio manager cannot assure that actual results will be consistent with these FLS.

Unless required by applicable law, Harvest Portfolios Group Inc. does not undertake, and specifically disclaim, any intention or obligation to update or revise any FLS, whether as a result of new information, future events or otherwise.

Sign up to receive our monthly updates